We describe a new approach to tolal pectoral implantation of cardioverter defibrillators with an endocardial defibrillation lead system. Endocardial lead configuration used was an FDA approved right atrial‐superior vena cavo defibriliation spring electrode, right ventricular bipolar sensing electrode, and a pectoral patch. Endocardial leads were implanted via a cephalic or an axillary venesection. Pectoral patch was placed in a sabmuscular position. In case of failure to obtain satisfactory thresholds, a small intercostal thoracofomy was performed via fhe same skin incision and patch placed over the epicardium instead of submuscular position and used with Ihe right atrial spring electrode. The device was implanted in the pectoral region, submuscularly, over the patch. Sixteen consecutive patients underwent this approach. With a submascular patch, adequate defibrillation thresholds (< 15 joules [J]) were obtained in 14 (87.5%) patients. In the other two, defibrillation thresholds of ≤ 15) were obtained with a epicardial patch. Pectoral implantation of the device was feasible in all 16 patients and none needed repositioning. Average postimplant hospital stay was 5 days. During follow‐up period (average 5 months), none of the patients reported any major local symptoms and no problems have been encountered in device interrogation. Thus, total pectoral implantation of the cardioverter defibrillator including the patch, leads, and the device is feasible. Furthermore, in case of foilure to obtain adequate defibrillotjon thresholds with submuscular patch, an epicardial patch can easily be implanted and allows 100% successful defibrillation at energy levels of ≤ 15 J with right atrial patch configuration.
|Number of pages||6|
|Journal||PACE - Pacing and Clinical Electrophysiology|
|State||Published - Jul 1993|
- implantable cardioverter defibrillator
- ventricular orrhythmias